Moreover, besides its clear single agent anti-tumor effect, our data also demonstrated the therapeutic potential of AXL-specific sdAb20-Fc in combination with the standard-of-care agents cytarabine and venetoclax. The gene discussed is AXL; the disease is neoplasm.